

Research & Development Portfolio:

45 projects and more than 20 new chemical entities, with over 20 ongoing clinical trials

June 2019



Drugs for Neglected Diseases *initiative*

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION	
	Screening	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access	
<p>Sleeping sickness</p>			SCYX-1330682 SCYX-1608210				Acoziborole		Fexinidazole* for <i>T.b. gambiense</i>	
							Fexinidazole for <i>T.b. rhodesiense</i>		Nifurtimox-eflornithine combination therapy (NECT)*	
<p>Leishmaniasis</p>	Screening	Leishmaniasis Hit-to-lead	DNDI-5421 DNDI-5610	DNDI-5561	DNDI-6148		New CL combination	New VL treatments (Latin America)	SSG&PM* (East Africa)	
		NTD Drug Discovery Booster Hit-to-lead	Amino pyrazoles	GSK3494245 DDD1305143	DNDI-0690			New treatments for PKDL	New treatments for HIV/VL	New VL treatments* (South Asia)
		Daiichi Sankyo Hit-to-lead	CF series	CpG-D35 for CL	GSK3186899 DDD853651			Miltefosine + paromomycin combination (Africa)		
			Leishmaniasis L205 Series							
<p>Chagas disease</p>	Screening	Chagas Hit-to-lead	Chagas C205 Series	Biomarkers		Fexinidazole	New benznidazole regimens		Benznidazole* paediatric dosage forms	
		NTD Drug Discovery Booster Hit-to-lead								
		Daiichi Sankyo Hit-to-lead								
<p>Filarial diseases</p>	Screening		Macrocyclic 3		Oxfendazole	Emodepside				
							TylAMac (ABBV-4083)			
<p>Mycetoma</p>							Fosravuconazole			
<p>HIV</p>							4-in-1 (ABC/3TC/LPVr)		Super-booster therapy* for children with HIV/TB	
										2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC
<p>Hepatitis C</p>							Ravidasvir + sofosbuvir	Ravidasvir		
<p>Malaria <small>(Implementation transferred to the Medicines for Malaria Venture in 2015)</small></p>									Fixed-dose combination ASAQ*	
										Fixed-dose combination ASMQ*

+ New chemical entity

*Treatments delivered by DNDi

Main R&D Partners*

Sleeping sickness

Accelera, Italy; Advinus Therapeutics Ltd, India; Aesica, UK; Amatsi Aquitaine (formerly Bertin Pharma), France; Analyticon Discovery Gmbh, Germany; Aptuit, Italy; Asinex Corporation, United States; Avista Pharma (formerly SCYNEXIS), USA; Biotrial, France; Bureau d'Etude d'Ingénierie -Ste Dina Sarl, Guinea; Cardibase, France; CBCO, DR Congo; Centipharm, France; Creapharm, France; Drugabilis, France ; Eurofins-Optimed, France; HAT Platform; Institut de Recherche pour le Développement, France; Institut National de Recherche Biomédicale, DR Congo; Institute of Tropical Medicine Antwerp, Belgium; Laboratoire La Référence, Guinea; Laboratory of Microbiology, Parasitology, and Hygiene, University of Antwerp, Belgium; Luxembourg Institute of Health, Luxembourg; Médecins Sans Frontières; National Control Programmes of the Democratic Republic of Congo, the Central African Republic, and of Guinea; Pace University, USA; Patheon, UK; Pfizer Inc., USA; Pfizer Inc. (formerly Anacor Pharmaceuticals Inc.), USA; PhinC, France; RCTs, France; Sanofi, France; SGS, Belgium; SGS, France; Swiss Tropical and Public Health Institute, Switzerland; Theradis Pharma, France; Trade Factors Overseas Ltd, Great Britain; WHO-NTD (Neglected Tropical Diseases department).

Leishmaniasis

AbbVie, USA; Accelera, Italy; Academic Medical Center in Amsterdam, the Netherlands; Addis Ababa University, Ethiopia; Advinus Therapeutics Ltd, India; Amatsi Aquitaine (formerly Bertin Pharma), France; Amc Medical Research B.V, the Netherlands; Amudat Hospital, Uganda; Aptuit, Italy; Analysis Ltd R.A.K, United Arab Emirates; Astellas Pharma Inc., Japan; AstraZeneca, Sweden and UK; Auckland University, New Zealand; Banook group, France; BaseCon, Denmark; Bayer, Germany; Bioascent, UK; BioAster, France; Bio Zeq Kenya Ltd, Kenya; Brasilia University, Brasilia, Brazil; Bristol-Myers Squibb, USA; Celgene Corporation, USA; Centre for Drug Candidate Optimisation, Monash University, Australia; Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), LN Bio, Brazil; Charles River Laboratories (Wil Research), France and the Netherlands; Crystallise!, Switzerland; Daiichi Sankyo Company, Limited, Japan; Daiichi Sankyo RD Novare Co., Ltd, Japan; Drug Discovery Unit, University of Dundee, UK; El du Pont de Nemours, USA; Eisai Co., Ltd., Japan; Epichem, Australia; Eurofins Cerep, France; Eurofins Panlabs Thailand, Thailand; Eurofins Panlabs, USA; Eurofins-Optimed, France; Foundation for Innovative New Diagnostics, Switzerland; GeneDesign Inc., Japan; Gilead Sciences, USA; GlaxoSmithKline, Spain and UK; Gondar University Hospital, Ethiopia; Griffith Institute for Drug Discovery, Griffith University, Australia; Hospital Sao José de Doencas Infecciosas, Fortaleza; Hypha Discovery Ltd, UK; Iktos, France; Institut Pasteur Korea, South Korea; Institute of Endemic Disease, Khartoum University, Sudan; Institute of Medical Sciences, Banaras Hindu University, India; Institute of Microbial Chemistry, Japan; Institute of Tropical Medicine Antwerp, Belgium; Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Brazil; Instituto de Física, Universidade de São Paulo, Brazil; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Instituto de Química, Universidade Estadual de Campinas, Brazil; Instituto de Salud Carlos III, Spain; International Centre for Diarrhoeal Disease Research, Bangladesh; Johnson & Johnson, USA; Kacheliba District Hospital, Kenya; Kala Azar Medical Research Centre, India; Kenya Medical Research Institute, Kenya; Kitasato Institute for Life Sciences, Japan; Laboratory of Microbiology Parasitology and Hygiene, University of Antwerp, Belgium; Lambda Therapeutic Research Ltd., India; LEAP Platform; London School of Hygiene & Tropical Medicine, UK; Makerere University, Uganda; Médecins Sans Frontières, Spain; Médecins Sans Frontières, the Netherlands; Medicines for Malaria Venture, Switzerland; Merck KGaA, Germany; Merck, USA; Ministry of

Health, Neglected Tropical Disease Directorate, Ethiopia; Ministry of Health, Neglected Tropical Diseases Unit, Leishmaniasis Programme, Kenya; Ministry of Health, Neglected Tropical Diseases Unit, Leishmaniasis Programme, Sudan; Ministry of Health, Leishmaniasis Control Programme, Uganda; Montes Claros State University, Montes Claros, Brazil; Nagasaki University, Japan; National Institute of Pathology, India; National Institutes of Health, USA; Netherlands Cancer Institute, the Netherlands; Nki Stichting Het Nerderland Kander Instituut, the Netherlands; Northwick Park Institute for Medical Research, UK; Novartis, Switzerland and USA; Ohio State University, USA; Osaka University, Japan; Paediatric Hospital Joao Paulo II – FHEMIG, Belo Horizonte, Brazil; Pentlands Management Systems Ltd, United Kingdom; Pkpdesign Sas, France; Pfizer Inc., USA; Pfizer Inc. (formerly Anacor Pharmaceuticals Inc.), USA; Piaui Federal University, Teresina, Brazil; Pierre Fabre Laboratories, France; Programa de Estudio y Control de Enfermedades Tropicales, Universidad de Antioquia, Medellin, Colombia; Programa Nacional de Leishmaniasis, Colombia; Quotient Sciences, United Kingdom; Rajendra Memorial Research Institute of Medical Sciences, India; Rene Rachou Research Center– Fiocruz-MG, Belo Horizonte, Brazil; Research Foundation of the Netherlands Cancer Institute, the Netherlands; Sandexis, UK; Sanofi Merial, USA; Sanofi, France; Sanofi-Aventis, France; Sara Pharm, Romania; Scynexis, USA; Sequella Inc, USA; Sergipe Federal University, Aracaju, Brazil; SGS, Belgium; Shionogi & Co., Ltd., Japan; SK Hospital, Mymensingh, Bangladesh; Swiss Tropical and Public Health Institute, Switzerland; Syngene, India; Takeda Pharmaceutical Company Limited, Japan; TB Alliance, USA; TCG Lifesciences, India; The Broad Institute of M.I.T and Harvard, USA; Thermosurgery Technologies Inc, USA; UBC, Switzerland; Universidade Estadual do Rio de Janeiro, RJ, Brazil; University of Cape Town, South Africa; University of Gedaref, Sudan; University Of Glasgow, United Kingdom; University of Gondar, Ethiopia; Uppsala University, Sweden; US Food and Drug Administration, USA; Walter Reed Army Institute of Research, USA; WHO-NTD (Neglected Tropical Diseases department); WHO-TDR (Special Programme for Research and Training in Tropical Diseases); WuXi AppTech, China; Zoetis (formerly Pfizer Animal Health), USA.

Chagas disease

AbbVie, USA; Astellas Pharma Inc., Japan; AstraZeneca, Sweden and UK; Barcelona Centre for International Health Research (CRESIB), Spain; Barcelona Centre for International Health Research, Spain; Barcelona Institute for Global Health (ISGlobal), Spain; Bayer, Germany; Bioascent, UK; Bioaster, France; Brazilian Biosciences National Laboratory, Brazil; Bristol-Myers Squibb, USA; Broad Institute of M.I.T and Harvard, USA; CEADES, Bolivia; Celgene Corporation, USA; Centre for Drug Candidate Optimisation, Monash University, Australia; Center of Excellence for Chagas Disease, United States; Centro de Chagas y Patologia Regional, Hospital Independencia, Argentina; Centro Nacional de Pesquisa em Energia e Materiais, LN Bio, Brazil; Chembridge Corporation, United States; Collective of Applied Studies and Social Development, Bolivia; Daiichi Sankyo Company, Limited, Japan; Daiichi Sankyo RD Novare Co., Ltd., Japan; Drug Discovery Unit, University of Dundee, UK; El du Pont de Nemours, USA; Eisai Co., Ltd., Japan; Exeltis, USA; Epichem, Australia; Eurofins, France; FP Clinical Pharma – Ethel Feleder, Argentina; Fundacio Investigacio Hospital General Valencia, Spain; Fundación Instituto de Investigaciones Biotecnológicas, Argentina; Hospital Universitario La Paz, Spain; GlaxoSmithKline, Spain and UK; Griffith Institute for Drug Discovery (GRIDD), Griffith University, Australia; Hospital Clínic de Barcelona, Spain; Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina; Hospital General de l'Hospitalet Consorci Sanitari Integral, Barcelona, Spain; Infectious Diseases Data Observatory, University of Oxford, UK; Infynity Biomarkers, France; Instituto de Física, Universidade de São Paulo, Brazil; Institut d'Investigacio Biomedica de Bellvitge,

Spain; Institute of Microbial Chemistry, Japan; Instituto Nacional de Parasitologia Dr Fatała Cháben, Argentina; Institut Pasteur Korea, South Korea; Instituto de Química, Universidade Estadual de Campinas, Brazil; Insud Pharma, Argentina; Johnson & Johnson, USA; Kitasato Institute for Life Sciences, Japan; International Development Research Center, Uruguay; Laboratorio ELEA PHOENIX, Argentina; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; LAT Research, Argentina; London School of Hygiene & Tropical Medicine, UK; Luxembourg Institute of Health, Luxembourg; McGill University, Canada; Médecins Sans Frontières; Medicines for Malaria Venture, Switzerland; Merck KGaA, Germany; Merck, USA; Ministry of Health, Colombia; Mundo Sano Foundation, Argentina; National Council of Scientific and Technological Research (INGEBI-CONICET), Argentina; NHEPACHA network; Northwick Park Institute for Medical Research, UK; Novartis, Switzerland and USA; Nucleus of Pharmaceutical and Cosmetics Development, Brazil; Pfizer Inc., USA; Pfizer Inc. (formerly Anacor Pharmaceuticals Inc.), USA; PhinC, France; Pierre Fabre Laboratories, France; Platform of Integral Care for Patients with Chagas Disease, Spain/Bolivia; Sandexis, UK; Sanofi Merial, USA; Sanofi, France; Sequella Inc, USA; Shionogi & Co., Ltd., Japan; Swiss Tropical and Public Health Institute, Switzerland; Syneos Health, Llc, United States; Takeda Pharmaceutical Company Limited, Japan; TB Alliance, USA; TCG Life Sciences, India; Texas Biomedical Research, USA; Unidad de Enfermedades Infecciosas, Seccion de Salud Internacional y Consejo al Viajero, Valencia, Spain; Universidad Autónoma Juan Misael Saracho, Bolivia; Universidad Mayor de San Simon, Bolivia; Universidad San Martin, Argentina; University Hospitals of Geneva, Switzerland; University of Cape Town, South Africa; University of Georgia Research Foundation, USA; University of Texas at El Paso, USA; Uppsala University, Sweden; Vall d'Hebron University Hospital, Spain; Walter Reed Army Institute of Research, USA; Washington University In St Louis, United States; WHO-TDR (Special Programme for Research and Training in Tropical Diseases); WuXi AppTech, China; Zoetis (formerly Pfizer Animal Health), USA.

Filarial diseases

AbbVie, USA; AWOL, UK; Analytical Services International, UK; Bayer, Germany; Bonn University Hospital, Institute of Medical Microbiology, Immunology and Parasitology, Germany; Celgene Corporation, USA; Commissariat à l'énergie atomique et aux énergies alternatives, France; Erasmus Medical Center, the Netherlands; Hammersmith Medicines Research, UK; Imperial College, UK; Institut Bouisson Bertrand, France; Institut de Recherche pour le Développement, France; Liverpool School of Tropical Medicine, UK; Mahidol University, Thailand; Merck, USA; National Museum of Natural History, France; Niche Science and Technology, UK; Northwick Park Institute for Medical Research, UK; Research Foundation for Tropical Diseases and the Environment, Cameroon; Salvensis, UK; University of North Carolina, USA; University of Health and Allied Sciences, Ghana; University of Liverpool, United Kingdom; Washington University in St Louis, USA.

Mycetoma

Eisai Co., Ltd., Japan; Erasmus Medical Center, the Netherlands; Free University Amsterdam, the Netherlands; Institute of Endemic Diseases, Khartoum University, Sudan; Mycetoma Research Centre, Soba University Hospital, Khartoum, Sudan; Radboud University Medical Center, Nijmegen, the Netherlands.

*Partners listed here include partners involved since the start of the project.

HIV

AMPATH, Kenya; AbbVie, USA; Associated Medical Sciences/PHPT International Research Unit, Thailand; Baylor College of Medicine Children's Foundation, Uganda; Centre for Disease Control and Prevention/President's Emergency Plan for AIDS Relief, USA; Cipla Ltd., India; Clinton Health Access Initiative, USA; Department of Health, South Africa; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa; Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, South Africa; Enhancing Care Foundation, South Africa; Epicentre, Uganda; Family AIDS Care and Education Services Project, Kenya; Gertrude's Children's Hospital, Kenya; i-Base, UK; Ifakara Health institute, Tanzania; Institute of Tropical Medicine, Antwerp; International Community of Women Living with HIV, Kenya; Joint Clinical Research Centre, Uganda; Kenya Medical Research Institute, Kenya; Kenyatta National Hospital, Kenya; Management and Development for Health, Tanzania; Mbagathi District Hospital, Kenya; Médecins Sans Frontières; Medical Research Council, UK; Ministries of Health of Kenya, Tanzania, Uganda, and Zimbabwe; Moi Teaching and Referral Hospital, Kenya; Moi University, Kenya; Necker Institute, France; NEPHAK, Kenya; Nyumbani Lea Toto Project, Children of God Relief Institute, Kenya; Perinatal HIV Research Unit, University of Witwatersrand, South Africa; Shandukani Research Centre, Wits Reproductive Health and HIV Institute, South Africa; St Lumumba Health Centre, Kenya; Stellenbosch University and Tygerberg Children's Hospital, South Africa; Swiss Tropical and Public Health Institute, Switzerland; University of Nairobi, Kenya; various academic partners in South Africa, Kenya, Uganda, and Tanzania.

Hepatitis C

Associated Medical Sciences/PHPT International Research Unit, Thailand; Clinical Research Malaysia, Ministry of Health, Malaysia; Doppel Farmaceutici, Italy; Hospitals of Geneva, Switzerland; Hospital Kuala Lumpur, Malaysia; Info Kinetics Sdn Bhd, Malaysia; Insud Pharma/Elea, Argentina; Kinapse Limited, United Kingdom; Médecins Sans Frontières, Ukraine; Ministry of Health, Thailand; Ministry of Industry, Science and Technology, Thailand; Mundo Sano Foundation, Argentina; Pharco Pharmaceuticals Inc, Egypt; Pharmaniaga, Malaysia; Presidio Pharmaceuticals, USA; Public Health Promotion Research and Training, Thailand; Toxipharm Laboratoire, France.